ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Partner program
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,937 companies indexed · Last updated: today
DirectoryIndustryPharmaceutical IndustryBaselTaysha Gene Therapies Switzerland GmbH
Taysha Gene Therapies Switzerland GmbH Logo
Verified· 2 sourcesTrust Score
Summary

About the company

Taysha Gene Therapies Switzerland GmbH is a biopharmaceutical company focused on discovering, developing and commercializing gene therapies for monogenic diseases of the central nervous system (CNS). Its lead clinical program targets Rett syndrome (TSHA-102), an intrathecally delivered AAV9 gene replacement therapy that incorporates a miRNA‑responsive auto‑regulatory element (miRARE) to regulate MECP2 expression.

AI-generated
Offering

Products & services

Industry:Pharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
4.1/5

Taysha Gene Therapies Switzerland GmbH

✓ Offered6
Gene therapy for Rett syndrome (TSHA-102)
Gene therapy for Rett syndrome with TSHA-102 as a one-time, intrathecally administered AAV9 gene transfer therapy; clinical development to treat the genetic cause, using miRARE technology.
Clinical studies
Clinical studies of TSHA-102 in Rett syndrome, including the REVEAL Pivotal Trial, the ASPIRE Trial, and Phase 1/2 studies for pediatric, adolescent and adult patients.
Scientific information and publications
Scientific information on gene therapy and the AAV9 strategy, posters and publications on TSHA-102, as well as background material for professionals.
Expanded Access
Case-by-case review for Expanded Access requests for investigational therapies outside clinical trials, provided certain requirements are met.
Patient affairs and patient information
Patient affairs, information materials, community letters, resources and support for patients, family members and patient groups related to Rett syndrome and TSHA-102.
Partnering and collaboration
Contact for potential partnerships and collaborations for early gene therapy programs in the field of central nervous system diseases.
Trust & reputation

ranQ Trust Score of Taysha Gene Therapies Switzerland GmbH: 4.1 out of 5.0

Trust Score4.1/ 5.0

High

x

Data basis 54% · As of October 2026

Without public customer reviews the score stays capped.

Taysha Gene Therapies Switzerland GmbH has no value in the Reputation area of the ranQ Trust Score because no data is available. The area carries 42% of the weighting and drops out of the calculation for this profile; it does not lower the score, only the reported data basis.
x
CriterionValueWeight
  • Review quality: No data point — the criterion is taken out of the weighting and does not lower the score.—24%
  • Review volume: No data point — the criterion is taken out of the weighting and does not lower the score.—10%
  • Review recency: No data point — the criterion is taken out of the weighting and does not lower the score.—8%
Taysha Gene Therapies Switzerland GmbH scores 67.8 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.64.612%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.55.07%
Taysha Gene Therapies Switzerland GmbH scores 83.3 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).83.322%
Taysha Gene Therapies Switzerland GmbH scores 100.0 out of 100 points in the Visibility area of the ranQ Trust Score. This area carries 8% of the weighting.
x
CriterionValueWeight
  • Website authority: Ahrefs' Domain Rating measures, on a scale of 0 to 100, how strongly a website is linked from other websites. For Swiss SMEs the range up to 40 is typical; the maximum is reached at 35.100.04%
  • Media authority: No data point — the criterion is taken out of the weighting and does not lower the score.—4%
Qualifications+0.00

Taysha Gene Therapies Switzerland GmbH reaches a ranQ Trust Score of 4.1 out of 5.0 — rated «High». No public customer reviews are available for this provider; the rating is based on the remaining criteria. The data basis is 54%, so the score is backed by part of the criteria. As of October 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Knowledge

No knowledge articles yet

Once Taysha Gene Therapies Switzerland GmbH has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Taysha Gene Therapies Switzerland GmbH in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Taysha Gene Therapies Switzerland GmbH by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Taysha Gene Therapies Switzerland GmbH to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Aeschenvorstadt 4
4051 Basel

At a glance

Legal form
Limited Liability Company
UID
CHE-474.536.494
Founded
2021 · 5 years
Last commercial register change
November 23, 2021
Employees
1 to 10
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.88.06%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.70.03%
    • Full methodology

    Similar companies

    AP
    Acadia Pharmaceuticals GmbH
    Basel
    AS
    Autolus Switzerland AG
    Basel
    SP
    Sumitomo Pharma Switzerland GmbH
    Basel
    SL
    S. L. A. Pharma AG
    Basel
    IS
    Immunovant Sciences GmbH
    Basel
    EP
    Eumedica Pharmaceuticals AG
    Basel
    AS
    Azafaros Switzerland AG
    Basel
    RS
    Roche Sapac AG
    Basel